CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir (Q43946040)

28 November 2017

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir (English)

1 reference

28 November 2017

1 reference

5

1 reference

28 November 2017

8

1 reference

28 November 2017

10

1 reference

28 November 2017

11

1 reference

28 November 2017

Josephson F

1

1 reference

28 November 2017

Allqvist A

2

1 reference

28 November 2017

Janabi M

3

1 reference

28 November 2017

Sayi J

4

1 reference

28 November 2017

Jande M

6

1 reference

28 November 2017

Mahindi M

7

1 reference

28 November 2017

Bottiger Y

9

1 reference

28 November 2017

Bertilsson L

12

1 reference

28 November 2017

language of work or name

English

0 references

publication date

28 February 2007

1 reference

Clinical Pharmacology & Therapeutics

28 November 2017

1 reference

28 November 2017

81

1 reference

28 November 2017

5

1 reference

28 November 2017

708-712

1 reference

Significance of the minor cytochrome P450 3A isoforms.

28 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

The genetic determinants of the CYP3A5 polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 phenotype-genotype correlations in a British population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Summary of information on human CYP enzymes: human P450 metabolism data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100117

1 reference

28 November 2017

1 reference